Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol.
Lotz JP, Curé H, Janvier M, Asselain B, Morvan F, Legros M, Audhuy B, Biron P, Guillemot M, Goubet J, Laadem A, Cailliot C, Maignan CL, Delozier T, Glaisner S, Maraninchi D, Roché H, Gisselbrecht C. Lotz JP, et al. Among authors: maraninchi d. Eur J Cancer. 2005 Jan;41(1):71-80. doi: 10.1016/j.ejca.2004.09.006. Eur J Cancer. 2005. PMID: 15617992 Clinical Trial.
High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease.
Fleury J, Legros M, Colombat P, Cure H, Travade P, Tortochaux J, Dionet C, Chollet P, Linassier C, Lamagnere JP, Blaise D, Viens P, Maraninchi D, Plagne R. Fleury J, et al. Among authors: maraninchi d. Leuk Lymphoma. 1996 Jan;20(3-4):259-66. doi: 10.3109/10428199609051616. Leuk Lymphoma. 1996. PMID: 8624465 Clinical Trial.
High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study.
Chabannon C, Cornetta K, Lotz JP, Rosenfeld C, Shlomchik M, Yanovitch S, Marolleau JP, Sledge G, Novakovitch G, Srour EF, Burtness B, Camerlo J, Gravis G, Lee-Fischer J, Faucher C, Chabbert I, Krause D, Maraninchi D, Mills B, Kunkel L, Oldham F, Blaise D, Viens P. Chabannon C, et al. Among authors: maraninchi d. Br J Cancer. 1998 Oct;78(7):913-21. doi: 10.1038/bjc.1998.601. Br J Cancer. 1998. PMID: 9764583 Free PMC article. Clinical Trial.
[High-dose chemotherapy in ovarian adenocarcinoma].
Lotz JP, Lhommé C, Pautier P, Couteau C, Gligorov J, Alexandre J, Selle F, Izrael V, Maraninchi D, Viens P. Lotz JP, et al. Among authors: maraninchi d. Bull Cancer. 2000 Jan;87(1):63-9. Bull Cancer. 2000. PMID: 10673633 Free article. Review. French. No abstract available.
Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients.
Viens P, Chabannon C, Pouillard P, Janvier M, Brugger W, Blay JY, Oberling F, Capdeville R, Newman C, Méresse V, Xu ZX, Platzer E, Van der Auwera P, Maraninchi D. Viens P, et al. Among authors: maraninchi d. J Clin Oncol. 2002 Jan 1;20(1):24-36. doi: 10.1200/JCO.2002.20.1.24. J Clin Oncol. 2002. PMID: 11773150 Clinical Trial.
314 results